Opus Genetics (STU:R3X1) Total Payout Ratio : 0.08 (As of May. 11, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Opus Genetics's current Total Payout Ratio is 0.08.

Opus Genetics Total Payout Ratio Historical Data

The historical data trend for Opus Genetics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Total Payout Ratio Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Payout Ratio

Get a 7-Day Free Trial

0.86

0.50

-0.25

0.92

0.08

Opus Genetics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Payout Ratio	Get a 7-Day Free Trial															-	0.34	0.20	0.06	-

Competitive Comparison of Opus Genetics's Total Payout Ratio

For the Biotechnology subindustry, Opus Genetics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opus Genetics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Total Payout Ratio falls into.

Save Embed

;

Save Embed

;

Opus Genetics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Opus Genetics's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-0.075	+	4.295	+	0)	/	-54.943
	=	0.08

Opus Genetics's Total Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-33.554
	=	0.00

Opus Genetics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Opus Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

IRD:USA R3X1:Germany

Address

8 Davis Drive, Suite 220, Durham, NC, USA, 27709

Website

https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Opus Genetics Headlines

No Headlines